DOCSLIB.ORG

HISTOLOGY Than That of the Nodular and Superficial Forms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HISTOLOGY Than That of the Nodular and Superficial Forms 1322 Practice of Oncology / Cancers of the Skin dome-shaped, or pedunculated papule, plaque, or nodule.77 It may the surface in a network of anastomoses of cords of cells in loose be difficult to distinguish clinically from amelanotic melanoma. connective tissue. The biologic behavior of the micronodular, infiltrating, and morpheaform (sclerosing) subtypes of BCC is more aggressive HISTOLOGY than that of the nodular and superficial forms. Infiltrative histology is seen in 15% to 20% of BCCs. Individual tumor islands manifest Histologic features defining BCC are aggregates of neoplastic small, irregular outlines with a spiky appearance that invade into basaloid cells stemming from the epidermis or the epithelium of and throughout the dermis. Palisading is characteristically absent. adnexal structures.75 Aggregates are organized as lobules, islands, The stroma is less myxoid than in the nodular form. In the mor- nests, or cords of cells that display an orderly arrangement of the ba- pheaform variant, small groups or cords of tumor cells often only saloid cell nuclei at the periphery, a palisading array. Occasionally, one to two cells in thickness infiltrate and dissect a dense, collag- central necrosis or cystic changes are seen within the tumor lob- enous stroma often parallel to the skin surface. Mixed histology is ules. Individual tumor cells have uniform, hyperchromatic, round frequently apparent in BCCs. Areas of follicular, sebaceous, ec- to oval nuclei. Mitotic figures are uncommon, but the presence of crine, or apocrine differentiation may also be seen in some BCCs. apoptotic cells and necrosis is frequently observed. Pleomorphic BCCs may contain focal areas of squamous differentiation, rang- variant of BCC shows tremendous variability of nuclear size and ing from individual dyskeratotic cells to keratin pearls. The term chromatism, as well as multiple mitoses and multinucleated giant basosquamous (metatypical) carcinoma denotes BCC with a pre- cells. A stromal retraction or clefting around the neoplastic aggre- dominance of mature, atypical keratinizing squamous component. gates is commonly seen in the dermis. An accumulation of mucin Biologic characteristics of a basosquamous carcinoma are more within and around the tumor lobules may be evident. similar to those of SCC with a possibility for metastasis. Histologic subtypes of BCC include nodular and micronod- The significance of histologic subtype lies in the correlation with ular, superficial, and infiltrative BCC (Fig. 92.6A,B). Nodular a tumor’s biologic aggressiveness. The infiltrative and micronodu- BCC accounts for approximately 50% of all histologic variants of lar types are the most likely to be incompletely removed by conven- BCCs and exhibits characteristic features as previously described. tional wide local excision (WLE). Rates of incomplete excision vary Superficial multifocal BCC accounts for approximately 15% from 5% to 17%.78 Incompletely excised infiltrative and micronod- of BCCs and is a broad lesion characterized by basophilic buds ular BCCs recur at rates of 33% to 39%. Recurrences after RT show extending from an atrophic epidermis into the papillary dermis. In a tendency toward infiltrative histology and squamous transforma- a two-dimensional view, tumor buds appear to be multifocal, but tion, and even recurrent BCC after excision or C&D may become upon three- dimensional imaging analysis they form a netlike pat- metatypical. Although historical reports in the literature suggested tern. Retraction artifact is present, as is peripheral palisading within that 60% of incompletely excised BCCs will not recur, none of the buds. FEP, which accounts for 1% of BCCs, is characterized these studies provided an appraisal of recurrence rates as a function by a polypoid lesion in which basaloid cells grow downward from of histologic subtype.68,69 In general, incompletely excised BCCs A B Figure 92.6 (A) Histology of nodular basal cell carcinoma (BCC). Nodular BCC is characterized by the presence of rounded tumor islands extending from the epidermis into the dermis. Peripheral palisading of nuclei is prominent, and surrounding retraction artifact may be present. (B) Histology of multifocal superficial BCC. Superficial BCC is characterized by basophilic buds extending from an atrophic epidermis into the papillary dermis. Retraction artifact is present, as is peripheral palisading within the buds. tahir99 - UnitedVRG Chapter 92 Cancer of the Skin 1323 should be removed completely, preferably by MMS, especially if were excluded. Imiquimod has been used off-label for the treat- they occur in anatomically critical areas such as the central zone of ment of nodular and infiltrative BCC.88,89 Although some studies the face, retroauricular sulcus, or periocular area. have shown favorable cure rates, imiquimod treatment of these tumors is generally not recommended as subclinical disease may persist and lead to late recurrence. TREATMENT The FDA-approved protocol for treating superficial BCC with topical 5-FU is twice-daily application for 3 to 6 weeks irrespective of Excisional surgery, MMS, and C&D have all been used to treat cir- tumor size or location. Longer treatment protocols with an average cumscribed, noninfiltrative BCCs. MMS is the treatment method 11 weeks are reported in the peer-reviewed literature. In a study of of choice for all recurrent and infiltrative BCCs, particularly if a 31 tumors treated twice daily for an average of 11 weeks, a 90% clear- tumor is located on the face.6,79 RT is best suited for poor surgical ance rate was observed histologically 3 weeks posttreatment.90 Topi- candidates and patients with extensive lesions not amenable to sur- cal PDT has also demonstrated efficacy in the treatment of BCC. gery.80,81 RT is not indicated for recurrent or morpheaform lesions Clearance rates for BCC using ALA or MAL PDT range from 76% and in patients with NBCCS. to 97% for superficial to 64% to 92% for nodular BCC after one C&D is frequently used by dermatologists in the treatment of to three treatments.26,28,91 Many studies of PDT for nodular BCC primary BCC. Knox82 noted cure rates as high as 98.3%. Kopf et involve curettage of the lesion prior to treatment, however, and it al.,83 in an earlier study, cited a significant difference in the cure is unclear if the response rate would be as successful without initial rates obtained between patients treated by private practitioners curettage. In a well-designed comparative trial, 601 patients with su- (94.3%) and those treated by trainees in the New York University perficial BCC were randomized to treatment with MAL PDT (two Skin and Cancer Unit (81.2%). This supports the premise that treatments given 1 week apart), imiquimod, or 5-FU according to C&D, although simple and cost-effective, is highly dependent FDA-approved protocols. Complete clinical remission at 1 year was on operator skill. Traditionally, it was recommended that the pro- found to be 72.8% for PDT, 83.4% for imiquimod (superior to PDT), cedure be repeated for three cycles, but histology, location, and and 80.1% for 5-FU (not statistically different from the other treat- behavior of the tumor should dictate the number of cycles. C&D ments). Patients treated with imiquimod or 5-FU were more likely should be reserved for small or superficial BCCs, not located on the to report bothersome local side effects of the treatment, however.92 midface, in patients who may not tolerate more extensive surgery. Historically, systemic therapy for BCC was limited to cytotoxic Surgical excision offers a unique advantage of histologic evalu- chemotherapy that was marginally effective as salvage therapy for ation of the excised specimen. It has been demonstrated that metastatic disease. Elucidation of the critical role of abnormal 4-mm margins are adequate for removal of BCC in 98% of cases hedgehog signaling in BCC, however, has led to development of of nonmorpheaform BCC of <2 cm in diameter.78 Extending the a novel class of molecularly targeted small molecule inhibitors of excision into subcutaneous fat generally is adequate for a small Smoothened, most notably vismodegib.74 Based on a seminal trial primary BCC. of 33 patients with metastatic BCC and 63 patients with locally OF ONCOLOGY PRACTICE MMS permits superior histologic verification of complete advanced BCC not amenable to surgical therapy, vismodegib was removal, allows maximum conservation of tissue, and remains approved (2012) for treatment of advanced BCC (either metastatic cost- effective as compared with traditional excisional surgery for or not amenable to surgery or radiation).73 With once daily oral NMSCs including BCCs.4,6 In a large study of treatment of primary dosing of 150 mg vismodegib, 30% of patients with metastatic BCC by Rowe et al.,84 MMS demonstrated a recurrence rate (RR) BCC and 43% of patients with locally advanced BCC had an of 1% over 5 years. This was superior to all other modalities, includ- objective response (at least 30% decrease in size of tumors), and ing excision (RR = 10%), C&D (RR = 7.7%), RT (RR = 8.7%), 21% of patients with locally advanced BCC had complete clinical and cryotherapy (RR = 7.5%). In a similar study of recurrent BCC, resolution of tumors. None of the patients with metastatic BCC treatment with MMS demonstrated a long-term RR of 5.6%.85 In had a complete response. Adverse events in the trial were com- that treatment group, MMS was superior to all other modalities, mon, including serious adverse events in 25% of patients and fatal including excision (RR = 17.4%), RT (RR = 9.8%), and C&D (RR adverse events in 7% of patients. Most common adverse events = 40%). MMS is the preferred treatment for morpheaform, recur- in this and other trials were muscle spasms, alopecia, dysgeusia rent, poorly delineated, high-risk, and incompletely removed BCC, leading to weight loss, fatigue, diarrhea, and hyponatremia, and and for those sites in which tissue conservation for function and cos- between 12% and 54% of patients discontinued therapy because mesis is imperative.
Load more

Recommended publications
  • Clinical Dermatology Notice
    This page intentionally left blank Clinical Dermatology Notice Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The editors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the editors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of such information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs. a LANGE medical book Clinical Dermatology Carol Soutor, MD Clinical Professor Department of Dermatology University of Minnesota Medical School Minneapolis, Minnesota Maria K. Hordinsky, MD Chair and Professor Department of Dermatology University of Minnesota Medical School Minneapolis, Minnesota New York Chicago San Francisco Lisbon London Madrid Mexico City Milan New Delhi San Juan Seoul Singapore Sydney Toronto Copyright © 2013 by McGraw-Hill Education, LLC.
    [Show full text]
  • Cutaneous Manifestations of Systemic Disease
    Cutaneous Manifestations of Systemic Disease Dr. Lloyd J. Cleaver D.O. FAOCD FAAD Northeast Regional Medical Center A.T.Still University/KCOM Assistant Vice President/Professor ACOI Board Review Disclosure I have no financial relationships to disclose I will not discuss off label use and/or investigational use in my presentation I do not have direct knowledge of AOBIM questions I have been granted approvial by the AOA to do this board review Dermatology on the AOBIM ”1-4%” of exam is Dermatology Table of Test Specifications is unavailable Review Syllabus for Internal Medicine Large amount of information Cutaneous Multisystem Cutaneous Connective Tissue Conditions Connective Tissue Diease Discoid Lupus Erythematosus Subacute Cutaneous LE Systemic Lupus Erythematosus Scleroderma CREST Syndrome Dermatomyositis Lupus Erythematosus Spectrum from cutaneous to severe systemic involvement Discoid LE (DLE) / Chronic Cutaneous Subacute Cutaneous LE (SCLE) Systemic LE (SLE) Cutaneous findings common in all forms Related to autoimmunity Discoid LE (Chronic Cutaneous LE) Primarily cutaneous Scaly, erythematous, atrophic plaques with sharp margins, telangiectasias and follicular plugging Possible elevated ESR, anemia or leukopenia Progression to SLE only 1-2% Heals with scarring, atrophy and dyspigmentation 5% ANA positive Discoid LE (Chronic Cutaneous LE) Scaly, atrophic plaques with defined margins Discoid LE (Chronic Cutaneous LE) Scaly, erythematous plaques with scarring, atrophy, dyspigmentation DISCOID LUPUS Subacute Cutaneous
    [Show full text]
  • Copyrighted Material
    1 Index Note: Page numbers in italics refer to figures, those in bold refer to tables and boxes. References are to pages within chapters, thus 58.10 is page 10 of Chapter 58. A definition 87.2 congenital ichthyoses 65.38–9 differential diagnosis 90.62 A fibres 85.1, 85.2 dermatomyositis association 88.21 discoid lupus erythematosus occupational 90.56–9 α-adrenoceptor agonists 106.8 differential diagnosis 87.5 treatment 89.41 chemical origin 130.10–12 abacavir disease course 87.5 hand eczema treatment 39.18 clinical features 90.58 drug eruptions 31.18 drug-induced 87.4 hidradenitis suppurativa management definition 90.56 HLA allele association 12.5 endocrine disorder skin signs 149.10, 92.10 differential diagnosis 90.57 hypersensitivity 119.6 149.11 keratitis–ichthyosis–deafness syndrome epidemiology 90.58 pharmacological hypersensitivity 31.10– epidemiology 87.3 treatment 65.32 investigations 90.58–9 11 familial 87.4 keratoacanthoma treatment 142.36 management 90.59 ABCA12 gene mutations 65.7 familial partial lipodystrophy neutral lipid storage disease with papular elastorrhexis differential ABCC6 gene mutations 72.27, 72.30 association 74.2 ichthyosis treatment 65.33 diagnosis 96.30 ABCC11 gene mutations 94.16 generalized 87.4 pityriasis rubra pilaris treatment 36.5, penile 111.19 abdominal wall, lymphoedema 105.20–1 genital 111.27 36.6 photodynamic therapy 22.7 ABHD5 gene mutations 65.32 HIV infection 31.12 psoriasis pomade 90.17 abrasions, sports injuries 123.16 investigations 87.5 generalized pustular 35.37 prepubertal 90.59–64 Abrikossoff
    [Show full text]
  • Dermatological Indications of Disease - Part II This Patient on Dialysis Is Showing: A
    “Cutaneous Manifestations of Disease” ACOI - Las Vegas FR Darrow, DO, MACOI Burrell College of Osteopathic Medicine This 56 year old man has a history of headaches, jaw claudication and recent onset of blindness in his left eye. Sed rate is 110. He has: A. Ergot poisoning. B. Cholesterol emboli. C. Temporal arteritis. D. Scleroderma. E. Mucormycosis. Varicella associated. GCA complex = Cranial arteritis; Aortic arch syndrome; Fever/wasting syndrome (FUO); Polymyalgia rheumatica. This patient missed his vaccine due at age: A. 45 B. 50 C. 55 D. 60 E. 65 He must see a (an): A. neurologist. B. opthalmologist. C. cardiologist. D. gastroenterologist. E. surgeon. Medscape This 60 y/o male patient would most likely have which of the following as a pathogen? A. Pseudomonas B. Group B streptococcus* C. Listeria D. Pneumococcus E. Staphylococcus epidermidis This skin condition, erysipelas, may rarely lead to septicemia, thrombophlebitis, septic arthritis, osteomyelitis, and endocarditis. Involves the lymphatics with scarring and chronic lymphedema. *more likely pyogenes/beta hemolytic Streptococcus This patient is susceptible to: A. psoriasis. B. rheumatic fever. C. vasculitis. D. Celiac disease E. membranoproliferative glomerulonephritis. Also susceptible to PSGN and scarlet fever and reactive arthritis. Culture if MRSA suspected. This patient has antithyroid antibodies. This is: • A. alopecia areata. • B. psoriasis. • C. tinea. • D. lichen planus. • E. syphilis. Search for Hashimoto’s or Addison’s or other B8, Q2, Q3, DRB1, DR3, DR4, DR8 diseases. This patient who works in the electronics industry presents with paresthesias, abdominal pain, fingernail changes, and the below findings. He may well have poisoning from : A. lead. B.
    [Show full text]
  • Table I. Genodermatoses with Known Gene Defects 92 Pulkkinen
    92 Pulkkinen, Ringpfeil, and Uitto JAM ACAD DERMATOL JULY 2002 Table I. Genodermatoses with known gene defects Reference Disease Mutated gene* Affected protein/function No.† Epidermal fragility disorders DEB COL7A1 Type VII collagen 6 Junctional EB LAMA3, LAMB3, ␣3, ␤3, and ␥2 chains of laminin 5, 6 LAMC2, COL17A1 type XVII collagen EB with pyloric atresia ITGA6, ITGB4 ␣6␤4 Integrin 6 EB with muscular dystrophy PLEC1 Plectin 6 EB simplex KRT5, KRT14 Keratins 5 and 14 46 Ectodermal dysplasia with skin fragility PKP1 Plakophilin 1 47 Hailey-Hailey disease ATP2C1 ATP-dependent calcium transporter 13 Keratinization disorders Epidermolytic hyperkeratosis KRT1, KRT10 Keratins 1 and 10 46 Ichthyosis hystrix KRT1 Keratin 1 48 Epidermolytic PPK KRT9 Keratin 9 46 Nonepidermolytic PPK KRT1, KRT16 Keratins 1 and 16 46 Ichthyosis bullosa of Siemens KRT2e Keratin 2e 46 Pachyonychia congenita, types 1 and 2 KRT6a, KRT6b, KRT16, Keratins 6a, 6b, 16, and 17 46 KRT17 White sponge naevus KRT4, KRT13 Keratins 4 and 13 46 X-linked recessive ichthyosis STS Steroid sulfatase 49 Lamellar ichthyosis TGM1 Transglutaminase 1 50 Mutilating keratoderma with ichthyosis LOR Loricrin 10 Vohwinkel’s syndrome GJB2 Connexin 26 12 PPK with deafness GJB2 Connexin 26 12 Erythrokeratodermia variabilis GJB3, GJB4 Connexins 31 and 30.3 12 Darier disease ATP2A2 ATP-dependent calcium 14 transporter Striate PPK DSP, DSG1 Desmoplakin, desmoglein 1 51, 52 Conradi-Hu¨nermann-Happle syndrome EBP Delta 8-delta 7 sterol isomerase 53 (emopamil binding protein) Mal de Meleda ARS SLURP-1
    [Show full text]
  • (2) October 2011\Protocol Book\Program-Speaker Page-Oc
    Chicago Dermatological Society October 2011 Monthly Educational Conference Program Information Continuing Medical Education Certification and Case Presentations Wednesday, October 12, 2011 David Fretzin Lecture Conference Host: Department of Dermatology University of Illinois at Chicago Chicago, Illinois University of Illinois at Chicago C UIC Student Center West (SCW) - 828 S. Wolcott Ave., 2nd Floor Registration, lectures, slide viewing, lunch and committee meetings C UIC Outpatient Care Center, Dermatology Clinic - 1801 W. Taylor, Suite 3E Patient viewing only (no registration at this location! Protocol books will be available.) UIC parking – Use the Wood Street Parking Structure, 1100 S. Wood at the intersection of (Wood & Grenshaw, just south of the UIC Outpatient Care Center) See reverse side for detailed campus map From the Eisenhower Expressway, exit at Ashland/Paulina. Proceed south on Ashland to Taylor. Turn west on Taylor approximately two blocks to Wood St. Turn south on Wood for the entrance to the parking lot. Program Conference Locations Student Center West (SCW) – 828 S. Wolcott, 2nd Floor Dermatology Clinic, 1801 W. Taylor St., Suite 3E 8:00 a.m. Registration Opens Student Center West, 2nd floor Foyer 9:00 a.m. - 10:00 a.m. Resident Lecture – SCW Chicago Room A-C "Spectrum of CD30+ Lymphoproliferative Diseases" Samuel Hwang, MD, PhD 9:30 a.m. - 10:45 a.m. Clinical Rounds Patient & Poster Viewing Dermatology Clinic, Suite 3E Slide Viewing Student Center West, Room 213 A/B 11:00 a.m. - 12:15 p.m. General Session - SCW Chicago Room A-C FRETZIN LECTURE: "An Update on Th17 Cells in Psoriasis" Samuel Hwang, MD, PhD 12:15 p.m.
    [Show full text]
  • 21 Genodermatoses
    . 21 . 21.2 The Ichthyoses 21 Genodermatoses Although this chapter is devoted to genodermatoses, many acquired disorders are also considered when they seem to fit into the general clinical picture. For example, acquired forms of porokeratosis are considered along with the less common in- herited ones. Genodermatoses 21.1 MIM Code What..................................................................................... is the MIM Code? Victor A. McKusick, one of the giants of clinical human genetics, started using a numerical code when he began compiling his books entitled Mendelian Inheritance in Man. The books evolved into a website, OMIM (Online Mendelian Inheritance in Man), which today serves as the standard for clinical genetics and the most convenient way to acquire updated information on all genetic disorders. The MIM code is given throughout this book whenever it is relevant. The first digit identifies the pattern of diagnosis: 1 = autosomal dominant inheritance; 2 = auto- somal recessive inheritance; 3 = X-linked inheritance. .....................................................................................How to Use OMIM 1 Simply enter ONIM in Google or any search engine and you will land on OMIM—or enter www.ncbi.nlm.nih.gov/OMIM. 2 Search OMIM. 3 Enter the MIM code, or a key word or two if you are looking for a syndrome or set of findings. 4 You will see a list of disease descriptions likely to be relevant to your query; chose whichever ones seem most useful. 5 Now you can read an update about the disease, the gene, find extensive references, or be linked to Medline. 21.2 The Ichthyoses Overview..................................................................................... The primary ichthyoses are a heterogenous group of inherited disorders featuring ex- cessive scale.
    [Show full text]
  • Copyrighted Material
    1 Index Note: Page numbers in italics refer to figures, those in bold refer to tables and boxes. References are to pages within chapters, thus 58.10 is page 10 of Chapter 58. A definition 87.2 congenital ichthyoses 65.38–9 differential diagnosis 90.62 A fibres 85.1, 85.2 dermatomyositis association 88.21 discoid lupus erythematosus occupational 90.56–9 α-adrenoceptor agonists 106.8 differential diagnosis 87.5 treatment 89.41 chemical origin 130.10–12 abacavir disease course 87.5 hand eczema treatment 39.18 clinical features 90.58 drug eruptions 31.18 drug-induced 87.4 hidradenitis suppurativa management definition 90.56 HLA allele association 12.5 endocrine disorder skin signs 149.10, 92.10 differential diagnosis 90.57 hypersensitivity 119.6 149.11 keratitis–ichthyosis–deafness syndrome epidemiology 90.58 pharmacological hypersensitivity 31.10– epidemiology 87.3 treatment 65.32 investigations 90.58–9 11 familial 87.4 keratoacanthoma treatment 142.36 management 90.59 ABCA12 gene mutations 65.7 familial partial lipodystrophy neutral lipid storage disease with papular elastorrhexis differential ABCC6 gene mutations 72.27, 72.30 association 74.2 ichthyosis treatment 65.33 diagnosis 96.30 ABCC11 gene mutations 94.16 generalized 87.4 pityriasis rubra pilaris treatment 36.5, penile 111.19 abdominal wall, lymphoedema 105.20–1 genital 111.27 36.6 photodynamic therapy 22.7 ABHD5 gene mutations 65.32 HIV infection 31.12 psoriasis pomade 90.17 abrasions, sports injuries 123.16 investigations 87.5 generalized pustular 35.37 prepubertal 90.59–64 Abrikossoff
    [Show full text]
  • General Physical Examination for a Cardiovascular Patient
    Published online: 2019-07-16 THIEME 42 Clinical Rounds General Physical Examination for a Cardiovascular Patient Jyotsna Maddury1 Shagun Aggarwal2 1Department of Cardiology, Nizam’s Institute of Medical Sciences Address for correspondence Jyotsna Maddury, MD, DM, FACC, (NIMS), Punjagutta, Hyderabad, Telangana, India FESC, FICC, Department of Cardiology, Nizam’s Institute of Medical 2Department of Medical Genetics, Nizam’s Institute of Medical Sciences (NIMS), Punjagutta, Hyderabad 500 082, Telangana, India Sciences (NIMS), Punjagutta, Hyderabad, Telangana, India (e-mail: [email protected]). Ind J Car Dis Wom 2019;4:42–49 The “innocent eye, which should see the world afresh, does Skin not see it at all.”1 1. Cyanosis and clubbing: Cyanosis and clubbing were The general physical examination is important in patients described in detail in earlier issues of this journal. with cardiovascular disease for specific diagnosis, to assess 2. Telangiectasia and hemangiomas: Cyanosis due to the severity and progression of the disease and, in some the right-to-left shunt through the pulmonary arterio- cases, even to know the therapeutic response. venous fistulas along with telangiectasia on the lips, tongue, and mucous is seen in Osler-Rendu-Weber General Appearance syndrome. Tight, shiny skin with telangiectasias is due to scleroderma. Endothelial cell malignancy is called Examination of the patient starts by observing the patient hemangiomas, which are different from the vascular when he/she enters the room. We have to pay attention to malformations (►Fig. 1). Cardiac lesions in scleroderma the patient’s functional age, posture, and general condi- are pulmonary arterial hypertension, myocardial, peri- tion. If the patient is suffering from acute pain, the severity cardial, and endocardial diseases.2 Even long exposure of the pain is perceived by seeing the face, the presence of to radiation such as in chronic total occlusion (CTO) diaphoresis, and posture he/she adapts.
    [Show full text]
  • Cutaneous Manifestations of Systemic Disease
    Cutaneous Manifestations of Systemic Disease Dr. Lloyd J. Cleaver D.O. FAOCD Northeast Regional Medical Center A.T.Still University/KCOM Assistant Vice President/Professor ABOIM Board Review Disclosure I have no financial relationships to disclose I will not discuss off label use and/or investigational use in my presentation I do not have direct knowledge of AOBIM questions I have been granted approvial by the AOA to do this board review Dermatology on the AOBIM ”1-4%” of exam is Dermatology Table of Test Specifications is unavailable Review Syllabus for Internal Medicine Large amount of information Cutaneous Multisystem Cutaneous Connective Tissue Conditions Connective Tissue Diease Discoid Lupus Erythematosus Subacute Cutaneous LE Systemic Lupus Erythematosus Scleroderma CREST Syndrome Dermatomyositis Lupus Erythematosus Spectrum from cutaneous to severe systemic involvement Discoid LE (DLE) / Chronic Cutaneous Subacute Cutaneous LE (SCLE) Systemic LE (SLE) Cutaneous findings common in all forms Related to autoimmunity Discoid LE (Chronic Cutaneous LE) Primarily cutaneous Scaly, erythematous, atrophic plaques with sharp margins, telangiectasias and follicular plugging Possible elevated ESR, anemia or leukopenia Progression to SLE only 1-2% Heals with scarring, atrophy and dyspigmentation 5% ANA positive Discoid LE (Chronic Cutaneous LE) Scaly, atrophic plaques with defined margins Discoid LE (Chronic Cutaneous LE) Scaly, erythematous plaques with scarring, atrophy, dyspigmentation DISCOID LUPUS Subacute Cutaneous
    [Show full text]
  • An Osteopathic Approach to Raynaud's Phenomenon
    Volume 27 JAOCDJournal Of The American Osteopathic College Of Dermatology pg. 12 An Osteopathic Approach to Raynaud’s Phenomenon Also in this issue: Tinea Faciei Presenting as a Perioral Dermatitis Cutaneous Pili Migrans Misdiagnosed Vicks VapoRub™ for Onychomycosis? last modified on December 19, 2013 2:08 PM JOURNAL OF THE AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY Page 1 JOURNAL OF THE AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY 2013-2014 AOCD OFFICERS PRESIDENT Suzanne Sirota-Rozenberg, DO, FAOCD PRESIDENT-ELECT Rick Lin, DO, FAOCD FIRST VICE-PRESIDENT Alpesh Desai, DO, FAOCD SECOND VICE-PRESIDENT Karthik Krishnamurthy, DO, FAOCD THIRD VICE-PRESIDENT Daniel Ladd, DO, FAOCD Editor-in-Chief IMMEDIATE PAST-PRESIDENT Karthik Krishnamurthy, DO Bradley Glick, DO, FAOCD SECRETARY-TREASURER Jere J. Mammino, DO, FAOCD TRUSTEES John P. Minni, DO, FAOCD Bryan Sands, DO, FAOCD Sponsors: Danica Alexander, DO, FAOCD Reagan Anderson, DO, FAOCD Bayer Michael Whitworth, DO, FAOCD AuroraDx Tracy Favreau, DO, FAOCD Immediate Past-President Medicis David L. Grice, DO, FAOCD Ranbaxy EEC Representatives James Bernard, DO, FAOCD JAOCD Michael Scott, DO, FAOCD Founding Sponsor Finance Committee Representative Steven K. Grekin, DO, FAOCD AOBD Representative Stephen Purcell, DO, FAOCD Executive Director AOCD • 2902 N. Baltimore St. • Kirksville, MO 63501 Marsha A. Wise, BS 800-449-2623 • FAX: 660-627-2623 • www.aocd.org COPYRIGHT AND PERMISSION: Written permission must be obtained from the Journal of the American Osteopathic College of Dermatology for copying or reprinting text of more than half a page, tables or figures. Permissions are normally granted contingent upon similar permission from the author(s), inclusion of acknowledgement of the original source, and a payment of $15 per page, table or figure of reproduced material.
    [Show full text]
  • Controversies in the Management of Digital Mucous Cysts
    Volume 30 JAOCDJournal Of The American Osteopathic College Of Dermatology Controversies in the Management of Digital Mucous Cysts Also in this issue: Squamous Cell Carcinoma in Situ Treated with Imiquimod Cream HIV-Associated Kaposi Sarcoma Induced by IRIS Psuedoxanthma Elasticum in Flexural and Non-Flexural Folds last modified on November 19, 2014 3:43 PM JOURNAL OF THE AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY Page 1 JOURNAL OF THE AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY 2013-2014 AOCD OFFICERS PRESIDENT Suzanne Sirota-Rozenberg, DO, FAOCD PRESIDENT-ELECT Rick Lin, DO, FAOCD FIRST VICE-PRESIDENT Alpesh Desai, DO, FAOCD SECOND VICE-PRESIDENT Karthik Krishnamurthy, DO, FAOCD THIRD VICE-PRESIDENT Daniel Ladd, DO, FAOCD Editor-in-Chief SECRETARY-TREASURER Karthik Krishnamurthy, DO Jere J. Mammino, DO, FAOCD TRUSTEES John P. Minni, DO, FAOCD Bryan Sands, DO, FAOCD Danica Alexander, DO, FAOCD Reagan Anderson, DO, FAOCD Sponsors: Michael Whitworth, DO, FAOCD Tracy Favreau, DO, FAOCD Bayer Immediate Past-President AuroraDx David L. Grice, DO, FAOCD EEC Representatives Ranbaxy James Bernard, DO, FAOCD Michael Scott, DO, FAOCD Valeant Finance Committee Representative Steven K. Grekin, DO, FAOCD AOBD Representative Stephen Purcell, DO, FAOCD Executive Director Marsha A. Wise, BS AOCD • 2902 N. Baltimore St. • Kirksville, MO 63501 800-449-2623 • FAX: 660-627-2623 • www.aocd.org COPYRIGHT AND PERMISSION: Written permission must be obtained from the Journal of the American Osteopathic College of Dermatology for copying or reprinting text of more than half a page, tables or figures. Permissions are normally granted contingent upon similar permission from the author(s), inclusion of acknowledgment of the original source, and a payment of $15 per page, table or figure of reproduced material.
    [Show full text]